Allergan's Botox Will Target 1.3 Mil. Severe Primary Axillary Hyperhidrosis Patients

FDA clears Botox for the treatment of primary axillary hyperhidrosis that is inadequately managed with topical agents. An FDA Talk Paper states patients should be evaluated for other potential causes of the problem, such as hyperthyroidism, prior to treatment.